Phase 2b trial in 68 adults with ALS: PrimeC (celecoxib plus ciprofloxacin) had adverse event rates similar to placebo (66.7% vs 65.2%) but more drug-related events (20.0% vs 4.3%); the ALSFRS-R difference at 6 months was not significant (P=.12).
RCTn = 68
Cudkowicz et al. Safety and Efficacy of PrimeC in Amyotrophic Lateral Sclerosis: The PARADIGM Randomized Clinical Trial